Related Experiment Video
Updated: Aug 2, 2026
Bloodless Laparoscopic Partial Splenectomy Assisted by Bipolar Radiofrequency Excision Hemostatic Device
Published on: November 4, 2022
Pediatric splenectomy for hematologic disorders: two-decade experience and prophylactic cholecystectomy outcomes
Oguzhan Uzaslan1, Ali Ekber Hakalmaz1, Suheyla Ocak2
1Department of Pediatric Surgery, Cerrahpaşa Faculty of Medicine, Istanbul University- Cerrahpaşa, Yesilkoy, Istanbul, Turkey.
Insights
Splenectomy effectively treats hematologic diseases, improving blood counts and bilirubin levels. Prophylactic cholecystectomy is beneficial for patients with high bilirubin, especially in hereditary spherocytosis.
Area of Science:
- Pediatric Hematology
- Surgical Gastroenterology
- Clinical Outcomes Research
Background:
- Splenectomy is a key treatment for hematologic disorders.
- The indications and timing for prophylactic cholecystectomy after splenectomy are debated.
Purpose of the Study:
- To evaluate long-term outcomes of splenectomy in pediatric patients with hematologic diseases.
- To assess the role and outcomes of prophylactic cholecystectomy in this cohort.
Main Methods:
- Retrospective analysis of 87 patients undergoing splenectomy for hematologic disorders (2003-2023).
- Evaluation of hematologic parameters, bilirubin levels, cholelithiasis prevalence, and complications.
- Subgroup analyses by disease and age.
Main Results:
- Hereditary spherocytosis was the most common diagnosis (70.1%).
- Splenectomy led to significant improvements in hemoglobin and platelet counts across disease groups.
- Cholelithiasis was common in hereditary spherocytosis (65.6%) and thalassemia (50%).
- Prophylactic cholecystectomy was performed in 10 patients, with higher preoperative bilirubin in this group.
Conclusions:
- Splenectomy provides durable hematologic improvement with low complication rates.
- Prophylactic cholecystectomy may be warranted in patients with significant hyperbilirubinemia, particularly in hereditary spherocytosis.
- Total splenectomy is safe with appropriate vaccination and antibiotic protocols, preventing post-splenectomy sepsis.
Background:
While splenectomy remains a cornerstone treatment for certain hematologic diseases, controversy persists regarding the optimal timing and indications for prophylactic cholecystectomy. This study evaluates long-term outcomes from a large single-center series.
Methods:
We retrospectively analyzed 87 patients (48 male, 39 female) with hematologic disorders who underwent splenectomy between 2003 and 2023. Primary outcomes included improvement in hematologic parameters, resolution of bilirubinemia, prevalence of cholelithiasis, and complication rates. Subgroup analyses examined disease-specific outcomes and age-stratified results.
Results:
Hereditary spherocytosis was the predominant diagnosis (70.1%), followed by thalassemia (11.5%) and immune thrombocytopenia (ITP) (10.3%). The mean age at splenectomy was 9.6 years (range 3-17), with a mean interval from diagnosis to surgery of 4.3 years. Spleen size significantly differed across diseases, being largest in rare hematologic disorders (178 mm) and smallest in ITP (97.56 mm). Cholelithiasis was present in 65.6% of hereditary spherocytosis cases and 50% of thalassemia cases but was absent in ITP. Simultaneous cholecystectomy was performed in 55 patients (63.2%), including 10 prophylactic procedures. Postoperatively, hemoglobin levels increased by factors of 1.24, 1.13, and 1.25 in hereditary spherocytosis, thalassemia, and ITP, respectively. Platelet counts increased by factors of 2.24, 2.8, and 6.5, respectively. Bilirubin levels decreased significantly in all groups. Notably, preoperative total bilirubin was significantly higher (p = 0.016) in patients selected for prophylactic cholecystectomy (mean 4.17 mg/dL) compared to those without cholecystectomy (mean 1.92 mg/dL).
Conclusions:
Splenectomy offers durable improvements in hematologic parameters across various hematologic diseases, with minimal complications. Prophylactic cholecystectomy appears justified in patients with marked hyperbilirubinemia, even without cholelithiasis, particularly in hereditary spherocytosis. The absence of post-splenectomy sepsis in this series supports the continued role of total splenectomy when appropriate vaccination protocols and antibiotic prophylaxis are implemented.
More Related Videos
02:09Application of Laparoscopic Partial Splenectomy with Total Blood Flow Occlusion in Benign Splenic Lesions
Published on: December 20, 2024
04:00Laparoscopic Splenectomy with Pericardial Devascularization for Hypersplenism and Esophageal Variceal Hemorrhage Due to Portal Hypertension
Published on: November 15, 2024
